Published in Gene Therapy Weekly, July 20th, 2006
AlbudAbs are dAbs that specifically bind to serum albumin and can dramatically enhance the half-life and efficacy of any molecule attached to them. The granted patent covers two or more dAbs linked to one another, where at least one dAb binds to serum albumin. The patent is the first to grant of a series of filings based on Domantis' pioneering AlbudAb approach. Domantis' lead AlbudAb program will enter late stage preclinical testing this year.
Dr. Ian Tomlinson, Domantis'...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly